The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
T2EVOLVE
Würzburg, Germany
A
11-50 Employees
-
Key takeaway
T2EVOLVE is a key alliance focused on accelerating the development and increasing access to CAR-T cell therapy, a revolutionary cancer treatment that reprograms patients' immune cells to target and destroy cancer. The initiative also aims to provide guidance on integrating these therapies into the EU healthcare system.
Reference
Core business
T2Evolve | The homepage of T2EVOLVE, a consortium working to accelerate the process of developing CAR T-cell therapy in the European Union (EU).
T-CURX GmbH
Würzburg, Germany
A
1-10 Employees
2017
Key takeaway
T-CURX is a biotech company focused on developing innovative CAR-T cell therapies for personalized cancer immunotherapy. They utilize proprietary technologies and engineering methods to create first- and best-in-class CAR-T products, positioning themselves at the forefront of cancer treatment advancements.
Reference
Core business
T-CURX - Frontline Cancer Immunotherapy
T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
T-knife
Berlin, Germany
A
101-250 Employees
2018
Key takeaway
T-knife Therapeutics is focused on developing T cell receptor engineered T cell therapies (TCR-Ts) to combat solid tumors, particularly those with high unmet medical needs. Their innovative approach targets various tumor antigens, showcasing their commitment to advancing CAR-T cell therapy alternatives.
Reference
Core business
T cell receptor engineered T cell therapies | T-knife Therapeutics
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Miltenyi Biomedicine
Bergisch Gladbach, Germany
A
51-100 Employees
2019
Key takeaway
Miltenyi Biomedicine is actively developing CAR-T cell therapies, particularly for difficult-to-treat hematological cancers, as part of their commitment to innovative cancer treatments and regenerative medicine. Their CliniMACS® Cell Factories ensure compliance with GMP regulations for the manufacturing of genetically engineered cellular products.
Reference
Core business
Personalized cell and gene therapy | Miltenyi Biomedicine
Miltenyi Biomedicine GmbH develops innovative cell and gene therapies. We are focused on bringing cancer treatments and regenerative therapies to patients.
MediGene
Planegg, Germany
A
11-50 Employees
1994
Key takeaway
Medigene is focused on developing T cell immunotherapies, specifically TCR-T cell therapies, aimed at treating solid tumors. Their proprietary End-to-End Platform, which includes advanced technologies for TCR generation and optimization, enhances the safety, durability, and efficacy of these therapies, ultimately advancing their potential in clinical development for cancer patients.
Reference
Product
TCR-T Therapy Optimization - Medigene AG
The deployment of advanced technologies can enhance the therapeutic effects of TCR-T cells. Merging the TCR with diverse enhancement tools like our PD1-41BB switch receptor results in better efficacy and sustained immune responses, thus augmenting TCR-T cell functionality. Co-expression of CD40L-CD28 switch protein with TCRs can enhance T cell tumor penetration and enables to overcome ... Read more
SIRION BIOTECH
Planegg, Germany
A
11-50 Employees
2007
Key takeaway
SIRION Biotech specializes in optimizing adeno-associated vectors for gene therapy, providing comprehensive support throughout the cell and gene therapy development process, from early R&D to clinical applications. Their expertise in viral vector development and production is particularly relevant for advancing CAR-T cell therapy.
Reference
Core business
Cell and Gene Therapy at SIRION
SIRION supports the entire cell and gene therapy value chain.
HS Diagnomics GmbH
Berlin, Germany
A
1-10 Employees
2012
Key takeaway
HSDiagnomics is actively advancing CAR-T cell therapy through its innovative project focused on identifying and preclinically validating tumor-specific T-cell receptors (TCRs) for solid cancers. Utilizing their proprietary TCRsafe® technology, they can deliver comprehensive TCRbeta profiles, enhancing research and development efforts in T-cell therapies.
Reference
Core business
HS Diagnomics GmbH - T-cell profiles uncovered
Zellkraftwerk
Leipzig, Germany
A
1-10 Employees
-
Key takeaway
Canopy Biosciences specializes in innovative products and services for biomedical research, including CAR-T characterization. Their offerings support researchers in analyzing gene expression, which is crucial for advancing CAR-T cell therapy.
Reference
Product
CAR-T Characterization - Canopy Biosciences
CellGenix
Freiburg im Breisgau, Germany
A
51-100 Employees
1994
Key takeaway
Sartorius CellGenix is a prominent supplier of high-quality raw and ancillary materials essential for the CAR-T cell therapy market. Their extensive expertise in GMP manufacturing and development of cytokines, growth factors, and serum-free media supports the clinical trials and commercial production of advanced therapy medicinal products (ATMPs).
Reference
Core business
Sartorius CellGenix • Raw Materials for Cell & Gene Therapy
Leading manufacturer of high quality ancillary materials for cell & gene therapy • Preclinical & GMP Cytokines & Growth Factors • GMP Serum-free Media
CellServe GmbH
Berlin, Germany
A
1-10 Employees
2015
Key takeaway
CellServe GmbH is a biotechnology company that specializes in innovative cell therapies aimed at treating heart failure. Their focus on developing heart tissue-specific cells for regenerative medicine highlights their commitment to providing curative therapies that enhance patients' quality of life.
Reference
Core business
CellServe GmbH – The experts in regenerative medicine
Technologies which have been searched by others and may be interesting for you:
When exploring the CAR-T cell therapy industry in Germany, several key considerations come into play. Regulatory compliance is crucial, as the European Medicines Agency (EMA) oversees the approval of CAR-T therapies, necessitating adherence to stringent clinical trial protocols and safety standards. The competitive landscape features both established pharmaceutical giants and innovative biotech startups, fostering a dynamic environment for collaboration and investment. Understanding reimbursement policies is also essential, as these therapies can be expensive, and navigating health insurance coverage is vital for patient access. Additionally, the German market benefits from a robust healthcare infrastructure and a strong focus on research and development, presenting numerous opportunities for innovation. Challenges include high production costs and the complexity of manufacturing personalized therapies, which can hinder scalability. Environmental concerns around waste management and the sustainability of manufacturing processes are increasingly relevant, requiring companies to adopt eco-friendly practices. Lastly, the global market relevance of CAR-T therapies is growing, with Germany positioned as a key player in Europe, making it an attractive location for investment and collaboration in this cutting-edge field.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | Germany |
| Amount of fitting manufacturers | 443 |
| Amount of suitable service providers | 366 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1994 |
| Youngest suiting company | 2019 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Biotechnology, Other, Medical, Pharmaceuticals, IT, Software and Services
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
